文章：

非小细胞肺癌（NSCLC）新兴靶向疗法研究进展

Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)

原文发布日期：22 January 2025

DOI: 10.3390/cancers17030353

类型: Article

开放获取: 是

英文摘要：

Targeted therapies have changed the treatment landscape of non-small-cell lung cancer and led to improved patient survival across all stages of lung cancer. Newer advances in common and novel oncogenic drivers continue to occur at vigorous speed, making it challenging to stay up to date with the rapidly evolving field. In this article, we review the emerging perspectives in the treatment of actionable targets in lung cancer. We focus on the development of newer KRAS-directed therapies, particularly on non-G12C mutations, pan-RAS inhibitors, and RAS-GTP inhibitors. We also describe the current standard of care for EGFR- and ALK-altered NSCLC and dive into the novel treatments expected to be in the clinic soon. A similar approach is taken toward MET, HER2, RET, ROS1, and FGFR alterations as emerging targets in non-small-cell lung cancer. Finally, we conclude this review with the current body of evidence for targeting TROP-2 as a novel target, potentially of importance in post-targeted therapy scenarios.

摘要翻译： 

靶向治疗已改变了非小细胞肺癌的治疗格局，并在肺癌各阶段显著提升了患者的生存率。常见及新型致癌驱动因子的研究进展持续快速涌现，使得紧跟这一快速发展领域的步伐充满挑战。本文综述了肺癌可作用靶点治疗的新兴视角，重点探讨新型KRAS靶向疗法的进展，特别是针对非G12C突变、泛RAS抑制剂及RAS-GTP抑制剂的研究。同时，我们阐述了当前EGFR与ALK基因变异非小细胞肺癌的标准治疗方案，并深入探讨即将进入临床的新型疗法。对于MET、HER2、RET、ROS1及FGFR等非小细胞肺癌新兴治疗靶点的变异，本文也采用类似分析框架进行探讨。最后，我们总结了目前靶向TROP-2作为新型治疗靶点的证据体系，该靶点在靶向治疗后阶段可能具有重要临床意义。

原文链接：

Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)